Welcome to the Week in Review.
GLOBE & GUARD Face Industry Pushback as Details Take Shape
The proposed GLOBE and GUARD models are mandatory CMMI programs with savings potential for the Medicare program. The initiatives aim to use the rebate infrastructure of the Inflation Reduction Act to test alternative payment approaches for high-cost drugs and lower costs in Medicare Part B and Part D. However, key design choices warrant scrutiny. The models rely in part on manufacturer-submitted data to establish international pricing benchmarks, creating risk that incomplete or strategic reporting could blunt their impact. In addition, exemptions for manufacturers that enter into voluntary Most Favored Nation agreements could limit the programs reach if broadly applied. The GUARD model also runs the risk of increasing cost sharing for patients. P4AD submitted comments on both models recommending safeguards to strengthen transparency, durability, and affordability for patients. Early comments submitted by PhRMA and BIO suggest the industry is preparing legal challenges questioning CMS’s authority, leveraging their nearly-endless litigation resources in a standard pharma tactic that is currently being employed against Medicare Negotiation. GLOBE and GUARD have the potential to reduce Medicare spending, and the former could meaningfully lower out-of-pocket costs for patients — but their effectiveness will depend on both design integrity and the agency’s ability to withstand anticipated opposition. — [STAT News, P4AD, P4AD, STAT News, Endpoints News]
The State of Drug Pricing
While we welcomed President Trump’s strong rhetoric on drug prices during the State of the Union address, the administration’s current approach centers on voluntary direct-to-consumer and Most Favored Nation deals and falls short of systemic reform. These arrangements do not broadly lower drug prices across the market, and exclude many of the highest-cost and most widely used medications. The president called for Congress to codify an enforceable MFN-style policy, which could be a meaningful step toward bringing U.S. prices in line with those paid by other high-income countries, depending on the policy passed. However, any attempts at codification require the details of these MFN deals to be released — something PhRMA CEO Stephen Ubl has vehemently opposed as recently as last week. Lasting affordability requires structural reform that meaningfully constrains monopoly pricing power, including mandatory programs like Medicare negotiation that deliver measurable savings at the pharmacy counter. — [POLITICO, P4AD]
Novo to Lower Wegovy & Ozempic List Prices but Additional Action Still Needed
Novo Nordisk announced it will lower the list price of blockbuster GLP-1 drugs Ozempic and Wegovy to $675 a month starting January 1, 2027. While reductions in a drug’s list price are welcome — particularly for patients facing high deductibles or no coverage — many insurance plans still don’t cover GLP-1 drugs to treat obesity. This list price change is likely to benefit people with commercial insurance, as both drugs are included in the second round of Medicare negotiation, where the price will fall to $274 a month, roughly 60% lower than Novo’s announced list price — and on the same January 1, 2027 date. Unlike voluntary cuts, negotiated prices are enforceable, durable, and do not depend solely on the good will of the pharmaceutical industry. The contrast underscores a broader point: temporary discounts can shift headlines, but structural reform delivers more reliable savings for a broader swath of the population. — [Wall Street Journal, STAT News]
ICYMI
Last week, P4AD CEO Merith Basey joined The Washington Post Intelligence’s panel, “Washington’s New Push on Drug Pricing,” as well asPhRMA Executive Vice President of Policy and Research Elizabeth Carpenter for a discussion on drug pricing policies including Medicare negotiation, PBM reforms, rising launch prices, and the latest pricing proposals. You can watch the full briefing here. — [Washington Post]
Patient Advocate Spotlight: Susan Vigen
Condition: Severe overactive bladder and interstitial cystitis
Drug: Myrbetriq (Listed at $1,677 / 90 day supply, with a monthly copay that increased from $120 to $365 in 2024)
Background: Patient advocate from South Carolina
In Her Words: “Myrbetriq has a monthly copay responsibility for me that increased from $120 to $365 every 90 days starting in the fall of 2024. This is simply too expensive for me and while there is a generic version of the drug called Mirabegron, my insurance will not cover it. Thus, I am left constantly looking for cheaper pharmacies and ways to save.”
“As someone who used to work in the pharmaceutical industry for about 17 years on the data management side, I understand the cost of bringing a drug to market and the need for some profit making to be made, however, I am now the patient feeling the financial frustration.”
Subscribe to the WEEK IN REVIEW here.
WASHINGTON, D.C. — In response to this evening’s State of the Union Address and President Trump’s statements on prescription drug prices, which focused primarily on TrumpRx and codifying a Most Favored Nation framework, Patients For Affordable Drugs Now CEO Merith Basey issued the following statement:
“While we welcome the strong rhetoric about the urgent need to lower prescription drug prices, the reality is that nearly 50 percent of Americans are worried about their ability to afford a health care cost this year, and U.S. patients currently pay between four and eight times more than those in other high-income countries for the very same brand-name drugs.
The administration has announced voluntary, direct-to-consumer and Most Favored Nation agreements, but these arrangements do not automatically lower drug prices across the entire system, nor do they apply to most high-cost or widely used medications.
If Congress codifies a strong, enforceable MFN-style policy into law, it could be a meaningful step toward bringing U.S. prices in line with those paid by other high-income countries. The details will determine whether it will truly deliver lasting savings.
In a system that has long favored drug corporations over patients, Americans urgently need further structural reform that permanently limits the monopoly pricing power of drug companies and lowers costs at the pharmacy counter.”
Background
Protect and Expand Medicare Negotiation
Eliminate Patent Abuse and Increase Competition
###
Patients For Affordable Drugs Now is the only national, patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNow is bipartisan and does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more, visit: PatientsForAffordableDrugsNOW.org
Welcome to the Week in Review.
Pushback: Pharma’s “IRA Watchdog” Analysis Misrepresents Medicare Negotiation
A recent report from DLA Piper argues that Medicare drug price negotiation is failing to deliver meaningful savings to seniors, but the analysis relies on false assumptions and flawed methodology, misrepresenting the truth. DLA Piper houses IRA Watchdog, a group backed by Bristol Myers Squibb, AstraZeneca, Merck, and Eli Lilly — several of which are simultaneously suing to block negotiation. The report narrowly defines “savings” in a manner that does not account for all drug pricing provisions, excluding key reforms such as the out-of-pocket cap and $35 insulin cap, inflation rebates, and Part D redesign. The headline claim that “only 11% of seniors save” relies on a restrictive framing; the same analysis notes that 15% of beneficiaries take a negotiated drug and 73% of those beneficiaries see lower cost sharing. The report also characterizes drugs like Tradjenta entering renegotiation due to generic or biosimilar competition as a negative for patients. Tradjenta’s lower negotiated price may no longer go into effect, but it’s because the drug now has competition — and competition often drives prices even lower than negotiated rates. Furthermore, the analysis incorrectly attributes trends that predate Medicare negotiation, such as premium increases, to the IRA. In short, the analysis minimizes documented savings, overstates access concerns, and is intended to advance the industry’s efforts to weaken negotiation. Lawmakers shouldn’t be fooled by these claims and should understand the financial interests behind them. — [DLA Piper, P4ADNow, Bloomberg Law, FightPharma]
E&C Health Subcommittee Hearing Results In Familiar Finger-Pointing
Representatives from across the drug supply chain, including PhRMA, BIO, Pharmaceutical Care Management Association (PCMA), and other industry groups, testified before the House Energy & Commerce Health Subcommittee this week. Notably absent were any patient voices. As expected, PhRMA blamed PBMs, PBMs blamed drug makers, and the structural drivers of high list prices received less scrutiny than they warranted. Still, several members of the committee pressed on core affordability issues. Lawmakers challenged PhRMA’s repeated claim that high drug prices are necessary for innovation, while others called attention to the secrecy surrounding drugmakers’ MFN pricing deals with President Trump, prompting PhRMA’s COO, Lori Reilly, to tell Congress that “you’ll have to take our word” that the agreements are good for patients. Pharma demands transparency from other actors in the supply chain, but when it comes to the prices they set, they insist we just have to trust them. Members also highlighted patent thickets and exclusivity tactics that extend monopolies well beyond statutory protections, delaying generic competition and driving up costs. While each sector debated its share of the dollar, one fact remains clear: brand-name drug companies play the biggest role in determining what patients will ultimately pay. — [E&C, YouTube, YouTube, YouTube, Washington Post, POLITICO, Roll Call]
TrumpRx: Hype vs. Reality
TrumpRx.gov is officially live, but important questions remain about its scope and impact. For 33 of the 43 drugs currently listed, TrumpRx’s prices match those already available on GoodRx, and reporting from STAT News indicates that at least 18 drugs have lower-cost generics available elsewhere. TrumpRx excludes many of the most widely prescribed and high-cost medications, including blockbuster drugs like Keytruda and Eliquis. Drugs on TrumpRx are also done through voluntary deals, and we have few details on how long their inclusion will last. For a small subset of patients — particularly those on certain GLP-1 or IVF drugs — the discounts could be meaningful, but for most Americans, including many cash-paying patients who can already find lower prices elsewhere, the real-world impact is likely limited, despite being marketed as a life-changing solution for millions. — [P4AD, STAT News, CBS News, Barron’s, Fierce Pharma, Common Dreams]
AbbVie Files Lawsuit against Medicare Negotiation
Just two weeks after Botox and Botox Cosmetic were named as drugs to be included in the third round of Medicare Drug Price Negotiations, manufacturer AbbVie, has filed a lawsuit in the U.S. District Court for the District of Columbia challenging the program. AbbVie argues that, as a plasma-derived product, Botox should be ineligible for negotiation under CMS guidance. The company also claims the program violates the First and Fifth Amendments by compelling speech through the negotiation framework and interfering with private property rights – constitutional arguments that closely mirror those raised in earlier pharmaceutical industry lawsuits challenging the program. While courts have repeatedly rejected similar constitutional claims brought by other manufacturers, AbbVie’s assertion that Botox qualifies as exempt on the basis of being plasma-derived marks a new line of argument in the ongoing litigation against Medicare negotiation. Botox is not simply a cosmetic product – it’s also used to treat a range of serious chronic conditions. Yet AbbVie is suing to protect its billions in profits rather than allow Medicare to secure lower prices for nearly 400,000 people on Medicare who rely on these medicines. — [P4AD, Bloomberg Law, Reuters, Endpoints News, Fierce Pharma, BioSpace, Law360]
ICYMI
In addition to driving down prices, Medicare negotiation is also expanding coverage of included medications. A new analysis from KFF finds that in 2026, all Part D enrollees have coverage of the first 10 negotiated drugs — including all dosages and forms — as required through the IRA. Coverage rates improved for multiple formulations of 9 of the 10 drugs compared to 2025, with especially large gains for insulin products Fiasp and NovoLog and certain doses of the cancer drug Imbruvica. The impact of Medicare negotiation for patients extends far beyond lower negotiated prices. — [KFF]
Patient Advocate Spotlight: Stacy Dyke
Condition: Hemiplegic Migraines, Occipital Neuralgia, Idiopathic Intracranial Hypertension, and Fibromyalgia
Drugs: Nurtec, Spravato, Reyvow, Trudhesa, and Zavzpret (totaling ~$8,500 per month list price)
Background: Patient advocate from Shreveport, Louisiana
In Her Words: “I’m navigating a medical system that often feels designed against me. Each day is a battle against relentless pain, a battle made even harder by the exorbitant cost of treatment. I’ve cycled through countless medication trials, from ineffective generics to brand-name drugs that carry a hefty price tag — commonly ranging from $400 to $6,000 a month each, and forcing me into a continuous struggle to afford my medications. Life often feels like a never-ending game of chess, constantly strategizing to manipulate a broken system and anticipate the next move. This shouldn’t be our reality.”
Subscribe to the WEEK IN REVIEW here.
Welcome to the Week in Review.
TrumpRx Officially Launches
The Trump administration rolled out TrumpRx.gov, a new federal website intended to connect patients with manufacturer discounts on roughly 40 prescription drugs. While the program centralizes manufacturer-run discount and DTC offerings, it does not sell medications directly, and does not change how drug pricing works in the U.S. For most Americans, particularly the ~85% who have insurance, the site is unlikely to significantly lower their costs, as drugs purchased through TrumpRx do not count toward deductibles or out-of-pocket limits. While the program may offer short-term relief to some patients, it’s not a substitute for enforceable, system-wide reforms. TrumpRx was initially slated to release in January, with the delay speculated to be caused by concerns over federal anti-kickback laws. Patients in our community will soon learn if they can reliably access these discounts at the pharmacy counter, where the program will ultimately be tested and where affordability matters most. — [TrumpRx, Senate, Sen. Durbin, Public Citizen, White House, White House, STAT News, BioSpace, MedPage Today]
FTC Settles PBM Insulin Price-Gouging Case with Express Scripts
The FTC announced a settlement with Cigna’s Express Scripts, resolving claims that the pharmacy benefit manager engaged in practices that artificially inflated insulin prices and harmed patients. The settlement included welcome reforms designed to base patient cost-sharing on a drug’s net price, ensure fairer reimbursement for community pharmacies, and delink PBM compensation from list prices — similar to reforms included in the spending package passed earlier in the week, which focused on delinking in Medicare. CVS Caremark, Express Scripts, and OptumRx control roughly 80% of prescriptions filled in the U.S., and the FTC’s 2025 report found that PBMs generated $7.4 billion by inflating the prices of 51 lifesaving drugs between 2017 and 2022. The FTC’s cases against CVS Caremark and OptumRx remain ongoing. Ultimately, patients will judge the impact of this settlement by what they pay at the pharmacy counter. — [FTC, P4ADNow, FTC, Axios, New York Times, Endpoints News, STAT News, Bloomberg, Healthcare Dive, Pink Sheet]
Funding Package Includes Prescription Drug Reforms
P4AD-supported prescription drug pricing reforms were signed into law on Tuesday as part of the government spending package. The package included the so-called Q1/Q2 provision requiring clearer guidance on ingredient differences in generic drug applications to save generic manufacturers time and money in bringing lower-cost alternatives to market. And for the first time ever, Congress passed PBM reforms that would increase transparency and accountability by delinking PBM compensation from drug prices in Medicare Part D, curbing incentives to steer patients toward more expensive prescription drugs and bolstering pricing data reporting requirements. P4AD will continue to push for further reforms that tackle the root causes of high drug prices and rein in Big Pharma. — [Healthcare Finance, P4AD, Washington Post, Fierce Healthcare, BioSpace, Managed Healthcare Executive]
The Growing Success of Medicare Drug-Price Negotiation
In a new article published by the New England Journal of Medicine, Dr. Benjamin Rome and Dr. Aaron Kesselheim find that Medicare drug price negotiation is gaining durability and momentum. The authors note that the program will now have been implemented across two administrations using the same statutory process, strengthening its staying power, with its legality also being repeatedly upheld in court despite industry challenges. They warn that the most imminent threat comes not from the courts, but from pharma-backed carveouts like the ORPHAN Cures Act, which have already blocked negotiation for blockbuster drugs such as Keytruda and Opdivo, and new proposals to delay negotiation for small-molecule drugs, like the EPIC Act. P4AD strongly opposes these bills, and our patient advocates continue to fight relentlessly to halt industry efforts to weaken or roll back this critical program.
Senate Democrats Outline Three-Pillared Drug Pricing Plan
Senate Finance Committee Democrats sent a letter to their colleagues this week outlining their plans for drug pricing reforms. Authored by Ranking Member Wyden (D-OR), Sen. Cortez Masto (D-NV), Sen. Welch (D-VT), and Sen. Gallego (D-AZ), the letter outlined a three-pillar plan emphasizing the importance of Medicare negotiation and advocating for the program’s expansion, counteracting abusive practices and middlemen in the drug supply chain, and bolstering drug innovation by restoring NIH funding and reducing delays in FDA approval processes. With nine in ten Americans calling on Congress to take further action on lowering prescription drug costs, reforming U.S. drug pricing is broadly popular across the aisle. — [Bloomberg, Inside Health Policy]
Patient Advocate Spotlight: Judy Aiken
Condition: Psoriatic arthritis and psoriasis
Drugs: Enbrel ($2,355 / month, down from over $7,000 list price/month before negotiations)
Background: Retired nurse from Portland, Maine
In Her Words: “Seeing Enbrel on the list of drugs to be negotiated first allows me to take a deeper breath, have hope, and honestly live a better life. Enbrel’s high price has been a real burden, a constant anxiety. A better deal on this drug is life-changing for me and thousands of patients and me.”
“This year, my copay for my first refill of Enbrel was $850, much better than the whole $2,100 cap at once.”
Subscribe to the WEEK IN REVIEW here.
WASHINGTON, D.C. — This evening, the Trump administration rolled out TrumpRx.gov, a new federal website intended to connect patients with manufacturer discounts on certain high-cost prescription drugs. In response to the announcement, P4AD CEO Merith Basey released the following statement:
“It is no secret that Americans are desperate for lower drug prices, and efforts to bring U.S. prices in line with those in other high-income nations are urgently needed. We share the goal of addressing high drug prices and are encouraged to see the Administration keep this issue front and center.
The steep discounts on select medications will be especially welcomed by patients struggling to afford GLP-1s. However, these voluntary agreements lack clear enforcement mechanisms and still put the power to set and increase prices firmly in the hands of pharmaceutical corporations.
Patients in our community will soon learn if they can reliably access these discounts at the pharmacy counter, where the program will ultimately be tested and where affordability matters most.”
At the time of launch, TrumpRx.gov features discounted prices on 40 brand-name medicines offered by a limited number of manufacturers.
Drugs available through TrumpRx must be purchased with cash and do not count toward insurance deductibles or out-of-pocket limits. While some medications are offered through manufacturer coupon cards that may be used at local pharmacies, others are only available through manufacturers’ direct-to-consumer websites or a limited set of mail-order pharmacies. Pharmacies and manufacturers are not required to participate, and there is currently no known standardized process to ensure these discounts will be consistently accepted at the pharmacy counter.
The pricing commitments are voluntary and not backed by statute, with no clear penalties if manufacturers withdraw products or change terms. Most importantly, the program does not address drug list prices, leaving the underlying drivers of high costs untouched.
###
Patients For Affordable Drugs Now is the only national, patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNow is bipartisan and does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more, visit: PatientsForAffordableDrugsNOW.org
WASHINGTON, D.C. — Today, President Trump signed into law a government spending bill that includes bipartisan prescription drug pricing reforms long supported by Patients For Affordable Drugs Now. The provision known as Q1/Q2, previously included in the Lower Costs, More Transparency Act, and the PBM reforms incorporated in the package are key steps toward lowering prescription drug prices by strengthening competition and increasing transparency in the drug supply chain.
Merith Basey, CEO of Patients For Affordable Drugs Now, released the following statement:
“We’re encouraged to see the inclusion of several bipartisan reforms in today’s spending package that patients fought hard for. The U.S. is in urgent need of a prescription drug system that serves patients, not one that rewards middlemen and entrenched monopolies. Strengthening competition and increasing transparency are key to lowering prescription drug prices. One in three Americans is unable to afford their prescriptions, and Congress must go further to tackle the root causes of high drug prices and rein in Big Pharma.”
The package includes:
These measures were previously included in the bipartisan health package that nearly passed in December 2024.
Looking ahead, patients continue to call on Congress to take more aggressive action to lower prescription drug prices. While increased PBM guard rails are a meaningful first step towards increasing accountability and transparency, it will not independently solve the problem of high drug prices or rein in pharmaceutical monopolies.
Patients continue to urge lawmakers to confront more of the practices that keep drug prices high — including patent thickets, product hopping, and pay-for-delay deals — and to advance bipartisan competition reforms that would shorten monopoly periods and speed lower-cost generics and biosimilars to market.
###
Patients For Affordable Drugs Now is the only national, patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNow is bipartisan and does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more, visit: PatientsForAffordableDrugsNOW.org
Welcome to the Week in Review.
Medicare Negotiation Round Three Drugs Announced
The third round of expensive prescription drugs selected for Medicare negotiation were announced this week, covering medications that account for $27 billion in Medicare spending. The selected drugs treat a variety of chronic conditions — including cancer, diabetes, autoimmune diseases, asthma, and HIV — and several have been subject to recent price hikes by the industry, including Cimzia, which increased by $899 per kit, Entyvio, which increased by $748 per vial, and Xeljanz, which increased by $334 per package, underscoring the urgency of allowing Medicare to negotiate fairer prices. Predictably, PhRMA criticized the plans, but the stakes are clear: nearly 1.8 million people on Medicare rely on these drugs. From patients like Diane, who depends on Xeljanz and is forced to spend nearly her entire disability check in copays, and Dana, whose HIV medication, Biktarvy, costs thousands out of pocket each year, lower negotiated prices offer the promise of real relief. With earlier rounds projected to save patients $2.2 billion annually, round three builds on that momentum, even as the drug industry escalates attacks to block the program in the courts and via Congress. — [P4AD, AP, P4AD]
Impact of ORPHAN Cures Takes Shape
Wednesday’s Medicare negotiation announcement was a win for patients, but it was also notable for what was absent: the world’s best-selling drug Keytruda, a drug with nearly $30 billion worldwide in yearly sales. That omission is due to the passage of the ORPHAN Cures Act via OBBBA in July 2025, an unnecessary nearly $9 billion handout to the pharmaceutical industry that exempts drugs with multiple orphan indications from Medicare price negotiation, despite blockbuster revenues. As a result, prices for medications like Keytruda and Opdivo remain unchecked for years longer, leaving patients exposed to unaffordable prices. Pharma is pushing for even more giveaways like the EPIC Act, which would delay negotiation for small-molecule drugs, roughly 90% of all prescriptions. At a time when 86% of Americans on both sides of the aisle support granting Medicare the authority to negotiate prices for all drugs, efforts to weaken the program stand in clear opposition to both patient needs and public consensus. — [Drug Discovery Trends, The Hill, AV]
Rising Cost of Healthcare Top Worry for Americans
New polling from KFF reveals healthcare costs are now Americans’ top economic concern, eclipsing worries about housing, food, utilities, and gas. Two-thirds of the public (66%) say they are worried about affording health care for themselves or their families, and a majority (55%) report their health care costs have increased over the past year, with one in five saying those costs rose faster than food or utilities. Looking ahead, 56% expect health care to become even less affordable. Against that backdrop, 90% of Americans say that drug prices are too high, and nearly three-quarters blame that on the pharmaceutical industry. The takeaway for lawmakers is clear: reforms that lower drug prices align with voter priorities across party lines.— [KFF, Washington Post, AV]
ICYMI: On Wednesday, CMS Administrator Mehmet Oz met with Republicans on the Senate Finance Committee to discuss drug pricing strategy. The conversation’s focus was on the president’s most-favored-nation pricing strategy, according to insider reporting. — [POLITICO, Washington Post, STAT News]
Patient Advocate Spotlight: Marianne
Condition: Diabetes
Drugs: Trulicity ($280 per month)
Background: 66-year-old cosmetologist from Traverse City, Michigan
In Her Words: “I am on Medicare, and its cost is unbelievable with the additional cost of my medication Trulicity. With this medication, I am strapped financially, not knowing or exactly sure of where that money will come from. I am currently paying $280 a month for Trulicity, which is a huge financial burden. One would’ve thought life would be easier in old age! But I was wrong. We need lower-cost prescription drugs now because people like me need them without having to choose to give up food, heat, or electricity, as I do.”
Subscribe to the WEEK IN REVIEW here.
Welcome to the Week in Review.
Government Funding Health Package Advances PBM Reforms & Generic Competition
The House passed a government spending bill on Thursday that includes key drug price reforms that P4AD has consistently pushed for since 2023. The package incorporates the Q1/Q2 provision originally included in the bipartisan Lower Costs, More Transparency Act, which would address a crucial barrier to generic drug approvals by requiring the FDA to provide clearer guidance on ingredient differences in generic drug applications, saving generic manufacturers time and money in bringing lower-cost alternatives to market. A 2023 CBO estimate found that Q1/Q2 would save taxpayers $871 million over a decade. The bill also includes a provision that would delink PBM compensation from drug prices in Medicare Part D, curbing incentives to steer patients toward more expensive prescription drugs. It would also expand reporting requirements to increase transparency for plan sponsors. While these steps represent important steps forward, significant work remains to achieve the systemic reforms still needed to lower drug prices for everyone. The bill now moves to the Senate, which will be back in session on Monday. — [CBO, STAT News, Endpoints News]
Drugmaker Greed and Shameful Threats on Display at JPMorgan Healthcare Conference
Last week’s JPMorgan Healthcare Conference underscored that pharmaceutical executives view President Trump’s most-favored-nation (MFN) pricing push as a threat to be countered. Pfizer CEO Albert Bourla warned that if U.S. prices were lowered to match countries like France, Pfizer would stop selling new medicines there — signaling a willingness to hold entire countries hostage by restricting access to medicines in order to protect higher U.S. prices. Bristol Myers Squibb (BMS)’s executives echoed that approach, pointing to a December U.K. agreement in which the company raised prices after threatening to withhold a new schizophrenia drug, arguing the “deal did not go far enough.” The strategy is familiar: after President Trump’s July letters urging 17 drugmakers to align U.S. prices with those of other high-income countries, Eli Lilly announced plans to raise prices in Europe. What stood out at the JPM conference was how openly and callously executives discussed “the dealmaking calculus” behind these moves — using large portfolios to selectively raise prices or limit supply in lower-priced markets to preserve massive profit margins. Raising prices abroad is pharma attempting to game the system and shift costs elsewhere, and it does nothing to lower costs for U.S. patients. The takeaway was unmistakable: the industry is only focused on maximizing profits with little regard for the lives they harm. — [Financial Times, CNN, Endpoints News]
Supreme Court Eyes Patent Laws & Pharma Lawsuits
On Thursday, the Supreme Court rescheduled AstraZeneca’s petition, choosing to hold its decision until further notice. The company’s petition seeks to block the price reduction of its diabetes drug, Farxiga, and blood cancer drug, Calquence — the latest effort in the industry’s broader legal campaign to undermine or completely stall Medicare drug price negotiation. Separately, the Court agreed last week to review a case involving skinny labels. This long-standing legal protection allows generic manufacturers to compete with name brands without infringing on secondary patents. It’s a practice that’s allowed generic drugs to find a foothold in the market, despite the pharmaceutical industry working hard to manipulate the U.S. patent system and block competition. Research shows that the competition from one generic entering the market can drive a medication’s price down by 39%, with six or more competitors reducing it by as much as 95%. P4AD supports the protection of skinny labelling and the affordable generic alternatives it delivers for patients, and will be closely watching both cases as the Court weighs issues with major implications for drug prices and patient access. — [STAT News, FDA, SCOTUS, The Hill, Endpoints News]
Drug Affordability Takes Center Stage in House
The House held a series of hearings this week on healthcare and drug affordability. In a Budget Committee hearing, Rep. Doggett (D-TX) pushed back on pharma’s claim that high prices are necessary for innovation, noting that no other industry makes that argument and that much early-stage innovation comes from unprofitable startups. He pointed to stalled biosimilar approvals as a clear area for reform. In Thursday’s Health subcommittee hearing, Rep. Harshbarger (R-TN) and Rep. Trahan (D-MA) warned that vertical integration between PBMs, pharmacies, and insurers has concentrated market power and weakened competition. Rep. Mariannette Miller-Meeks (R-IA) went further, criticizing PBMs for using group purchasing organizations to sidestep oversight and extract additional revenue. The throughline was clear: high drug prices are not a partisan issue, and meaningful relief for patients will require bipartisan action. Real progress will depend on whether Congress translates this concern into action that delivers lower prices for patients. — [House, X, House, X]
Patient Advocate Spotlight: Patricia Sportsman
Condition: Chronic obstructive pulmonary disease (COPD)
Drugs: Trelegy ($563 per month) in addition to Symbicort and Albuterol
Background: Senior from Coos Bay, Oregon
In Her Words: “My Trelegy prescription used to only cost me around $300 for a 90-day supply, totalling about $100 a month, which was financially doable for my situation. That price, however, changed at the beginning of 2025 when I realized my monthly cost would be $563 per month.”
“This is unfathomable. What senior citizen has this type of money? I certainly don’t, and have thus gone without the medication for 2 months. This is why a negotiated price for Trelegy is so crucial and important to me. Drug companies have overpriced their medications for too long, but the Medicare Negotiation Program can prevent this from going any further, lowering costs for patients, like myself, and taxpayers.”
Subscribe to the WEEK IN REVIEW here.